Have any clinical studies been done for Acunol(TM), Eczemol, Psorizide Forte or Psorizide ULTRA?
A retrospective clinical study of 76 acne and/or rosacea subjects given Acunol™ indicates improvement as measured by subjective patient assessment; 89% of subjects showed at least moderate improvement. A retrospective clinical study of 88 psoriasis subjects given Psorizide® Forte indicates improvement as measured by subjective patient assessment; 87% of subjects showed at least moderate improvement. Clinical studies of 86 psoriasis subjects given oral doses of nickel sulphate and sodium bromide, two principal ingredients of Acunol™, Eczemol®, Psorizide® Forte & Psorizide® ULTRA, indicate a high degree of statistical significance in the improvement in psoriasis area and severity measurements (PASI score). Ninety-eight percent of subjects exhibited a moderate to marked improvement. A double blind placebo controlled study confirmed safety and efficacy, employing nickel and bromide from a nickel bromide source.
